Disturbances in metabolic, transport and structural genes in experimental colonic inflammation in the rat: a longitudinal genomic analysis

Olga Martínez-Augustin1, Manel Merlos2, Antonio Zarzuelo3, María Dolores Suárez1 and Fermín Sánchez de Medina* 3

Address: 1Department of Biochemistry and Molecular Biology II, CIBEREHD, School of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071 Granada, Spain, 2Palau Pharma, Pol. Ind. Riera de Caldes Avinguda Camí Reial 51-57, 08184 Palau-solità i Plegamans, Barcelona, Spain and 3Department of Pharmacology, CIBEREHD, School of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071 Granada, Spain

Email: Olga Martínez-Augustin - omartine@ugr.es; Manel Merlos - pharm.merlos@uriach.com; Antonio Zarzuelo - zarzuelo@ugr.es; María Dolores Suárez - msuarez@ugr.es; Fermín Sánchez de Medina* - fsanchez@ugr.es

* Corresponding author

Abstract

Background: Trinitrobenzenesulphonic acid (TNBS) induced rat colitis is one of the most widely used models of inflammatory bowel disease (IBD), a condition whose aetiology and pathophysiology are incompletely understood. We have characterized this model at the genomic level using a longitudinal approach. Six control rats were compared with colitic animals at 2, 5, 7 and 14 days after TNBS administration (n = 3). The Affymetrix Rat Expression Array 230 2.0 system was used.

Results: TNBS-induced colitis had a profound impact on the gene expression profile, which was maximal 5 and 7 days post-induction. Most genes were affected at more than one time point. They were related to a number of biological functions, not only inflammation/immunity but also transport, metabolism, signal transduction, tissue remodeling and angiogenesis. Gene changes generally correlated with the severity of colitis. The results were successfully validated in a subset of genes by real-time PCR.

Conclusion: The TNBS model of rat colitis has been described in detail at the transcriptome level. The changes observed correlate with pathophysiological disturbances such as tissue remodelling and alterations in ion transport, which are characteristic of both this model and IBD.

Background

Inflammatory bowel disease (IBD), comprising ulcerative colitis and Crohn's disease, is characterized by chronic and relapsing inflammation of the gastrointestinal tract. The pathogenesis of IBD is unknown, but it appears to be multifactorial in origin, and genetic, environmental and dietary factors are believed to be involved [1]. Animal models of IBD have been central to the investigation of the pathophysiology of the disease and are valuable tools for drug testing and development. Because IBD-like diseases do not occur spontaneously in animals, several animal models that mimic different aspects of the disease are currently used, including gene knockout, transgenic, chemical, adoptive transfer and spontaneous models [2].

Published: 17 October 2008

BMC Genomics 2008, 9:490 doi:10.1186/1471-2164-9-490

Accepted: 17 October 2008

This article is available from: http://www.biomedcentral.com/1471-2164/9/490

© 2008 Martínez-Augustin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
To date, no single model has reproduced all features of the human disease. One of the most widely used models in both pharmacological and pathophysiological studies (72 in the past year) is murine colitis induced by trinitrobenzenesulphonic acid (TNBS) [3-5]. This simple model is based on a single rectal administration of TNBS dissolved in ethanol. TNBS is a hapten that elicits an immune response when bound to tissue proteins, while ethanol contributes to disruption of the intestinal barrier. The result is a severe and prolonged degenerative inflammation of large parts of the colon sharing several clinical and molecular characteristics with Crohn’s disease. Specifically, the inflammation produced by the administration of TNBS-ethanol involves all layers of the intestinal mucosa and produces long-lasting damage with cell infiltration and ulcers, including protracted physiological dysfunction. Furthermore, both TNBS-ethanol administration to mice and human Crohn’s disease are characterized by Th1-driven inflammation with infiltration of macrophages and neutrophils, producing high levels of proinflammatory cytokines such as tumour necrosis factor, interleukin (IL)-1β and IL-6, followed by T cell infiltration, mainly of the CD4+ phenotype.

Genomic profiling of disease models is of interest for characterizing the pathological response at transcriptome level and identifying putative drug targets. Animal models may overcome many of the limitations of the application of genomic technology to humans, including the need for repeated encoscopy, the large genetic and phenotypic variability, and the difficulty of studying the initial stages of the disease. There have been a few attempts at gene expression profiling in IBD models [6-10]. In general, these studies have addressed acute colitis (48–72 h after induction), employed small microarrays (containing 87 and 1252 transcripts in two of the studies), have analysed large samples (augmenting internal genomic variation, which occurs along the longitudinal axis) and include modest validation experiments (6–14 genes). Although a recent study by te Velde et al. [8] used 20,000 transcript microarrays, the data were not validated. Only one of the studies was longitudinal [9]. Therefore, the present study represents the most ambitious and comprehensive investigation to date, using several microarrays to examine the progression of colitis at four time points, employing a genechip platform that includes more than 30,000 transcripts (Affymetrix Rat 230 2.0). Results were validated in a subset of almost 100 transcripts by using real-time PCR (qRT-PCR). The full results database, publicly accessible, will serve as a valuable reference for all researchers in the field. In fact, three pharmacological studies adopting this strategy are currently underway in our laboratory.

Methods
All reagents were obtained from Sigma (Barcelona, Spain) except where indicated.

Animals
Female Wistar rats (175–225 g) were used, housed in makrolon cages and maintained in air-conditioned animal quarters with a 12-h light-dark cycle. Animals had free access to tap water and were fed a standard chow diet (Panlab A04, Panlab, Barcelona, Spain). This study was carried out in accordance with the Directive for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes of the European Union (86/609/EEC), was approved by the Ethical Committee of the University of Granada and complies with the American Physiological Society’s Guiding Principles in the Care and Use of Animals.

Induction of colitis
Colitis was induced as previously described [11]. Briefly, rats were fasted overnight and anaesthetized with halothane. Under these conditions, rats were given 10 mg of TNBS dissolved in 0.25 ml of 50% ethanol (v/v) by means of a Teflon cannula inserted 8 cm into the anus. Rats were kept in a head-down position for an additional 30 s and returned to their cages.

Experimental design
Rats were randomly assigned to one of two different groups, a control (C, n = 6) group that received a saline enema and a TNBS group (n = 12) that received the TNBS challenge. Food and water intake and body weight were determined daily. To follow the progression of the colitis, three rats of the TNBS group were killed 2, 5, 7 and 14 days after the induction of colitis. Three control rats were killed on day 2 and the other three at the end (day 14) of the experiment. For the purpose of postgenomic validation, this experiment was repeated in order to perform qRT-PCR analysis on fresh samples. The magnitude and time course of the inflammatory response were similar in both experiments (data not shown).

Assessment of colonic damage
Animals were killed by cervical dislocation, and the entire colon was removed and placed on an ice-cold plate, cleaned of fat and mesentery, and blotted on filter paper. Each specimen was weighed and its length measured under a constant load (2 g). The large intestine was longitudinally opened and scored for visible damage on a 0 to 25 scale as previously described [12]. A sample for genomic analysis was obtained from the distal colon approximately 4.5 cm proximal to the anus, taking care to avoid any areas of necrosis. The colon was subsequently divided longitudinally into several pieces for biochemical determinations. The fragments were immediately frozen in liquid nitrogen and kept at -80°C until used. Myeloperoxidase activity was measured according to the technique described by Krawisz et al. [13].
**RNA extraction, microarray hybridization and data analysis**

RNA was extracted from homogenized full-thickness colonic tissues in Trizol® reagent (Invitrogen) and purified with RNeasy affinity columns (Qiagen). Quantity and integrity of RNA were assessed by spectrophotometry and 0.8% agarose gel electrophoresis, respectively. Sample labelling, hybridization, staining and scanning procedures were carried out using Affymetrix standard protocols [http://www.affymetrix.com](http://www.affymetrix.com). The microarray analysis was performed by Progenika Biopharma (Bilbao, Spain) on 18 GeneChip® Rat Expression Array 230 2.0 microchips (Affymetrix). Normalization and statistical analyses were carried out using GeneSpring v7.1 (Agilent). Gene ontology analysis was performed with GeneMapp/MappFinder [http://www.genmapp.org](http://www.genmapp.org)[14]. Specifically, biological process, cellular component and molecular function categories were scored with respect to the number of genes included in the *Rattus norvegicus* database that were measured in the microarray and the number of genes significantly affected by TNBS colitis in each category. The resulting z parameter [15] has positive values when the proportion of genes affected is higher than expected, and it was used to select the most representative gene ontology categories (i.e. those with z ≥ 4) at each time point. Non-redundant categories are shown, listing only the highest z value when nested categories exceeded the cutoff value at multiple levels. The k-means algorithm was applied to identify and group transcript changes over time in clusters. Only sequences with annotated gene identities that were present (intensity > 100 units) in at least 66% of samples per group in at least one group were considered. The data were analyzed by analysis of variance followed by Tukey post-hoc tests in order to reduce the false positive or type I error rate in inter-group comparisons. In addition, the Benjamini & Hochberg false discovery rate correction was applied to reduce the occurrence of type I error when comparing among genes. This procedure offers a reasonable balance between sensitivity and specificity. Data are expressed as fold change (mean ± SEM) over the control (uninflamed) group (n = 6) at each time point (TNBS colitis after 2, 5, 7 or 14 days). MIAME recommendations [16] were followed to ensure that all information needed to understand, interpret, reproduce and compare our results was given in detail. The data are accessible at the the European Bioinformatics Institute Arrayexpress database [http://www.ebi.ac.uk](http://www.ebi.ac.uk) reference E-MEXP-873).

**Postgenomic validation**

Postgenomic validation was carried out by measuring 93 of the genes in fresh samples (n = 3 per group) using qRT-PCR with TaqMan® Low Density Arrays (Applied Biosystems). Genes were selected to include both significantly and non-significantly changed genes pertaining to different families affected by inflammation, i.e., those related to transport, immunity or metabolism. The relative Ct values of each gene with respect to the reference gene (18S) were used to calculate the RQ (relative quantitation) parameter, which represents the change in mRNA expression compared to a control sample. The RQ was then used to calculate fold change ratios. Results are expressed as mean ± SEM.

**Results**

**TNBS colitis**

The morphological and biochemical features of TNBS colitis were consistent with previous reports by our group and other authors [4,5,12,17]. Thus, TNBS-treated rats suffered anorexia and loss of body weight (Fig. 1) associated with extensive mucosal damage, oedema, haemorrhage and early epithelial necrosis. Leukocyte infiltration was prominent, resulting in a significant increase in myeloperoxidase activity (Fig. 1). Epithelial regeneration gradually occurred from day 7 and was macroscopically complete by day 14. At 5 and 7 days, there was major submucosal fibrosis and scarring that resulted in a marked shortening of colonic length. Even after 2 weeks, treated rats showed significant differences with controls in colonic weight-to-length ratio and myeloperoxidase activity, among others (Fig. 1).

**Genomic analysis**

2340 genes were significantly modified at 2 days after TNBS instillation (1238 upregulated, 1102 downregulated). This number was almost doubled at day 5 (4266, 2073 of which were upregulated) and rose to 5752 (2356 upregulated) by day 7. The pool of altered gene expression...
fell to 1953 by day 14 (1146 upregulated), coinciding with a marked recovery from the inflammatory bout. The dendogram in Figure 2 shows that samples from TNBS colitic rats at each time point were clustered together, forming groups that significantly differed from control samples. As expected, many of the genes that showed significant changes are directly related to the inflammatory response, including genes for chemokines, cytokines and inflammatory markers such as Cd, Ptgs2, or Lyz (see below).

An additional set of three rats per experimental group was subjected to confirmatory analysis of 93 genes by qRT-PCR. This independent validation procedure for microarray analysis results has become standard in genomic studies, although our use of triplicate measurements may have made this step redundant. An excellent correlation was found between microarray and qRT-PCR data (0.89 regression coefficient, n = 1116, Fig. 3). Individual examples can be seen in other Figures (see below). Amplification was not possible with two of the selected genes, namely Defb1 and Htr6. In addition, neither Il6 nor Ifng could be detected in the control samples but both were measured in the colitis groups. Hence, although this is an unmistakable indication of significant induction, a fold change could not be calculated from the qRT-PCR data. The reason for this discrepancy is not known.

Table 1 shows some of the most relevant gene categories affected by TNBS colitis (pre-established gene ontology entries), which differed according to the time point during the inflammatory response. Thus, although the immune response categories predictably dominated at all time points, apoptosis appeared to play a pivotal role at days 2

Figure 2
Time course changes of gene expression in rat TNBS colitis. Sample clustering by two-way analysis of variance. Upregulated genes are shown in red and downregulated genes in green. The difference between TNBS colitis and control samples was greatest on day 7.
and 5 while extracellular matrix related genes were especially important at day 7, and a variety of processes and functions were present as leading gene ontology categories at day 14. Manual analysis of the genes showing the most pronounced changes in expression confirmed the importance of immunity/inflammation and tissue remodelling/matrix but also indicated the occurrence of wide changes in transport, metabolism and signalling (see below).

**Time course analysis**

The set of genes that was significantly altered by TNBS colitis underwent k-means clustering, a mathematical tool that groups genes with a similar time evolution profile. Most genes clustered to profiles that showed the highest increase (or decrease) at 5 and 7 days, usually peaking at 7 days or staying relatively constant between 2 and 7 days and decreasing or increasing at 14 days (data not shown). However, some atypical profiles were also detected. Thus, the expression of some genes was changed only at day 2 (50 genes, Table 2) or day 14 (57 genes, Table 3) while others were upregulated (Cybb, Nfil3, Cxcr4, Spn, Itgb2) or downregulated (Apol, Amn, Apoa1, Aldob, Cxcl14, Ckm, Slc26a3) at all or most time points. Therefore, somewhat unexpectedly, the time course of gene expression was largely parallel, with few outliers, although there were marked differences in the magnitude of changes. However, as explained above, there was a change over time in the clustering of gene groups according to gene ontology.

**Genes involved in the inflammatory response**

Many of the most severely affected genes were those directly involved in the inflammatory response, as expected (Fig. 4, see also Fig. 5 for validated genes). Chemokines were especially prominent, including neutrophil chemokines and other leukocyte-attractant molecules. Interleukin 1 and related TLR2 pathways were highly affected, and both converged in the activation of NF-κB. Nfkbia (encoding IκB-α) was markedly increased, indicating a trend to limit activation of this pathway. The intestinal inflammatory marker Alpl [18] was prominently upregulated, unlike Alpi and Alpi2, the intestinal isoforms of alkaline phosphatase (data not shown).

The prostaglandin biosynthetic pathway was strongly activated by TNBS through the concerted induction of Pla2g2a, Ptgs2, and Ptges, especially during the chronic phase (confirmed by qRT-PCR, data not shown). Other affected genes are related to cell adhesion, bacteria binding or reactive oxygen species generation. There were also marked changes in the expression of numerous transcripts involved in antioxidative defence, most of which were downregulated.

In addition, close examination of the expression level of a number of genes that act as inflammatory cell markers indicated the nature of the inflammatory infiltrate. Thus, TNBS colitis was characterized by an absence of significant changes in markers of T cells (Thy1, Tcrb, Tcrg, Zap70, Lck), B cells (Ptprc -B220-, Ms4a1 -Cd20-, Cd22, Cd79b) and NK cells (Baat, Ncam1 -Cd56-, B3gat1 -Cd57-). In contrast, several neutrophil/macrophage markers such as S100a8, Itgb2 (Cd18), Cd68, predicted, Csf1r, Cybb, Csf2rb1 and Lcn2 were significantly increased by inflammation, especially at days 5 and 7.

**Genes involved in metabolism**

Metabolism-related genes were highly affected (mostly decreased) by TNBS-induced colitis (Fig. 6 and also Fig. 7 for validated genes). They included genes participating in glycolysis, like Aldob and many different subunits of the pyruvate dehydrogenase complex (Dlat, Dld, Pdhb, Pdha1), B cells (Ptprc -B220-, Ms4a1 -Cd20-, Cd22, Cd79b) and NK cells (Baat, Ncam1 -Cd56-, B3gat1 -Cd57-). In contrast, several neutrophil/macrophage markers such as S100a8, Itgb2 (Cd18), Cd68, predicted, Csf1r, Cybb, Csf2rb1 and Lcn2 were significantly increased by inflammation, especially at days 5 and 7.

With regard to lipid metabolism, the fatty acid biosynthetic enzymes Fasn and Scd1 were inhibited, as was the related gene Acly. Several transcripts related to cholesterol biosynthesis and transport were also affected (Hmgcr, Srebfl, Bzrp, Dhc1r7, Dhc2r4, Apoa1, Abca1). In addition, both ApoE and the apolipoprotein B mRNA editing gene Apobec1 were upregulated, suggesting a higher lipopro-
### Table 1: Gene ontology categories most affected by TNBS colitis at different time points

|                    | Gene ontology category                                                                 | z value |
|--------------------|----------------------------------------------------------------------------------------|---------|
| **Day 2**          | **Biological process**                                                                  |         |
|                    | Positive regulation of anti-apoptosis                                                   | 5.033   |
|                    | Leukocyte chemotaxis                                                                    | 5.199   |
|                    | **Cellular component**                                                                  |         |
|                    | Phosphoinositide 3-kinase complex                                                       | 4.202   |
|                    | Chemokine activity                                                                      | 5.721   |
|                    | 1-Phosphatidylinositol 3-kinase activity                                                | 4.582   |
|                    | Unfolded protein binding                                                                | 4.022   |
|                    | **Molecular function**                                                                  |         |
|                    |                                                                                       |         |
| **Day 5**          | **Biological process**                                                                  |         |
|                    | Immune system process                                                                   | 6.507   |
|                    | Immune response                                                                        | 6.088   |
|                    | Defence response                                                                       | 6.025   |
|                    | Response to external stimulus                                                          | 5.402   |
|                    | Antigen processing and presentation of peptide antigen via MHC class II                 | 5.128   |
|                    | Lymphocyte mediated immunity                                                            | 4.962   |
|                    | Cell death                                                                             | 4.910   |
|                    | Response to other organism                                                              | 4.532   |
|                    | Leukocyte migration                                                                     | 4.506   |
|                    | Cytokine biosynthetic process                                                           | 4.484   |
|                    | Phagocytosis, recognition                                                               | 4.473   |
|                    | Positive regulation of lymphocyte differentiation                                       | 4.348   |
|                    | Vasculature development                                                                 | 4.320   |
|                    | Protein amino acid dephosphorylation                                                    | 4.289   |
|                    | Regulation of inflammatory response                                                     | 4.190   |
|                    | T cell differentiation                                                                  | 4.091   |
|                    | Peptide antigen transport                                                               | 4.044   |
|                    | Regulation of protein binding                                                           | 4.001   |
|                    | Organelle fusion                                                                       | 4.001   |
|                    | **Cellular component**                                                                  |         |
|                    | MHC class II protein complex                                                            | 4.900   |
|                    | Mitochondrial respiratory chain                                                         | 4.384   |
|                    | TAP complex                                                                            | 4.374   |
|                    | **Molecular function**                                                                  |         |
|                    | Haematopoietin/interferon-class (D200-domain) cytokine receptor activity                | 5.107   |
|                    | Protein tyrosine phosphatase activity                                                   | 4.871   |
|                    | Cytokine activity                                                                       | 4.600   |
|                    | Chemokine activity                                                                      | 4.277   |
|                    | NADH dehydrogenase activity                                                             | 4.133   |
|                    | Peptide antigen-transporting ATPase activity                                            | 4.044   |
|                    | Phosphatidylserine binding                                                              | 4.001   |
| **Day 7**          | **Biological process**                                                                  |         |
|                    | Leukocyte chemotaxis                                                                    | 4.936   |
|                    | Immune system process                                                                   | 4.332   |
|                    | Response to external stimulus                                                          | 4.323   |
|                    | Antigen processing and presentation of exogenous peptide antigen                        | 4.124   |
|                    | **Cellular component**                                                                  |         |
|                    | Extracellular matrix part                                                               | 5.849   |
|                    | Proteinaceous extracellular matrix                                                     | 4.931   |
|                    | Collagen                                                                               | 4.674   |
|                    | Basement membrane                                                                      | 4.280   |
|                    | Actin filament                                                                         | 4.115   |
|                    | **Molecular function**                                                                  |         |
|                    | Extracellular matrix constituent                                                       | 4.710   |
| **Day 14**         | **Biological process**                                                                  |         |
|                    | Defence response                                                                        | 5.420   |
|                    | Prophyrin catabolic process                                                             | 5.286   |
|                    | Immune response                                                                        | 5.082   |
|                    | Lymphocyte homeostasis                                                                  | 5.029   |
|                    | DNA damage response, signal transduction by p53 class mediator                          | 4.414   |
|                    | Glial cell migration                                                                    | 4.414   |
|                    | Leukocyte activation                                                                    | 4.366   |
|                    | Inflammatory response                                                                   | 4.362   |
|                    | RNA destabilization                                                                    | 4.316   |
|                    | Positive regulation of interferon-gamma production                                      | 4.316   |
|                    | Heme oxidation                                                                         | 4.316   |
tein biosynthesis, although ApoE may also play a protective role against lipopolysaccharide [19]. A number of other metabolic pathways appeared to be altered by TNBS colitis, including purine de novo biosynthesis, arginine and heme catabolism.

**Genes involved in signalling**

Many transcripts involved in cell signalling were changed by TNBS colitis, including genes encoding proteins that participate in cAMP/protein kinase A and calcium/protein kinase C pathways, phosphatases, various regulatory proteins and a number of transmitter/hormone receptors, including P2ry6, Htr2b, Prl, Sstr1, Tacr2 and Thra. In addition, Ace was modestly increased only on day 14, suggesting a possible local increase in angiotensin II production (Fig. 8).

The signalling-related genes that exhibited the highest changes in expression included Gp49b and Plek. Gp49b encodes an immunoglobulin-like receptor expressed in myeloid cells that appears to counter-regulate the cytokine and chemokine attraction of neutrophils [20]. The function of Plek appears to be related to the regulation of macrophage phagocytosis [21].

**Genes involved in transport**

TNBS colitis influenced the expression of many transport-related transcripts, including genes that participate in ionic transport, e.g. Slc9a2, Slc9a3 (Nhe2-3), Scnn1a and Slc26a3 (Dra), which mediate Na+K+ absorption, and the Na+/K+/pump subunit Atp1a1 and Slc12a2 (Nkcc2), all of which were inhibited. However, the chloride channel Cftr was not affected. Three aquaporins (Aqp3, 8 and 11) were also repressed in TNBS colitis, whereas Aqp9 was upregulated. Many other nonionic transporters and ionic channels were altered (Fig. 9 and Fig. 10 for validated genes). Interestingly, there was upregulation of Slc7a7, which is involved in the basolateral transport of arginine, lysine and ornithine by epithelial cells and activated monocytes [22], suggesting increased availability of iNOS substrate.

**Genes involved in tissue remodelling**

Following the gene ontology analysis, a manual search of the most severely affected genes confirmed the dramatic changes in the expression of many genes involved in matrix deposition, muscle plasticity and angiogenesis (see Figs. 11 and 12 for validated genes). These include Igf1 (validated) and Igfbp5, genes that may regulate tissue remodelling by increasing collagen synthesis and cell proliferation. Several procollagen/collagen isoforms were increased, as well as genes involved in collagen processing and synthesis or in collagen and elastin fibre cross-linking (Lox, Tgm1 – both validated-). A number of metalloproteases and multiple cytoskeletal genes were increased, especially during the chronic phase.

**Discussion**

The main features of the TNBS model of colitis have been well defined. Ethanol causes direct toxic damage to the epithelium, which in turn grants TNBS access to the colonic mucosa, where it acts as a hapten. Although the toxic effect of ethanol is a requisite for TNBS to act effectively, the immunogenic nature of the ‘chronic’ phase has been unequivocally established by various authors [23–25]. Without TNBS, ethanol produces only a short-lived inflammatory reaction that resolves without sequelae and was therefore not of interest in the present study. During the ‘chronic’ phase, TNBS rat colitis shares a number of features in common with IBD, e.g., transmural inflammation (Crohn’s disease only), abnormal ion transport, diarrhoea, fibrosis and abnormal intestinal motility. Furthermore, TNBS rat colitis is amenable to treatment with corticoids, sulfasalazine or tacrolimus, making it an attractive model for the preclinical testing of putative IBD drugs. Our aim was to perform a detailed genomic characterization of the model.

The TNBS colonic inflammatory response was characterized by a marked increase in the expression of multiple genes involved in inflammation/immunity, including cytokines, chemokines, adhesion molecules, eicosanoid-
related genes, and a number of effectors and cell markers. There was a dramatic increase in Il1b, Il1a, Il6, Tgfb1 and Tnf and in various chemokine and chemokine receptors. In addition, a nonsignificant increase was observed in the pivotal Il23a and Ifng cytokine genes, which was found to be significant after re-examination using the more sensitive qRT-PCR. Although no protein data are available, it is tempting to speculate that the combined upregulation of

| Table 2: Genes modulated specifically at day 2 |
|-----------------------------------------------|
| Gene symbol | Gene name                                      | FC   | SEM  |
| Hla-dmb     | Major histocompatibility complex, class II, DM beta | 9.13 | 0.47 |
| Fbxl7_predicted | F-box and leucine-rich repeat protein 7 (predicted) | 8.46 | 3.35 |
| Acot12      | Acyl-CoA thioesterase 12                       | 8.19 | 3.28 |
| Pri8a2      | Prolactin family B, subfamily a, member 2       | 7.86 | 2.22 |
| Tmod1       | Tropomodulin 1                                 | 6.66 | 0.79 |
| Sds         | Serine dehydratase                             | 4.57 | 0.71 |
| Adcyap1r1   | Adenylyl cyclase activating polypeptide 1 receptor 1 | 4.56 | 0.54 |
| Sp2         | Sp2 transcription factor                       | 4.05 | 0.56 |
| Vmd2I1_predicted | Vitelliform macular dystrophy 2-like protein 1 (predicted) | 2.80 | 0.32 |
| Cenh2       | Corticotropin releasing hormone                 | 2.65 | 0.26 |
| Fzd4        | Frizzled homolog 4 (Drosophila)                | 2.64 | 0.14 |
| Igfbp5      | Insulin-like growth factor binding protein 5    | 2.44 | 0.30 |
| Cpg2        | CPG2 protein                                   | 2.32 | 0.08 |
| Lss         | Lanosterol synthase                            | 2.27 | 0.08 |
| Reil         | Reelin                                         | 2.10 | 0.17 |
| Atca2a_predicted | Ataxia, cerebellar, Cayman type (caytaxin) (predicted) | 2.05 | 0.06 |
| Ptk3c2g     | Phosphatidylinositol 3-kinase, C2 domain containing, gamma polypeptide | 2.02 | 0.25 |
| Fmo2        | Flavin containing monoxygenase 2               | 1.97 | 0.22 |
| S1c13a5     | Solute carrier family 13 (sodium-dependent citrate transporter), member 5 | 1.90 | 0.11 |
| Xlkd1_predicted | Extra cellular link domain-containing 1 (predicted) | 1.81 | 0.15 |
| Vps4a       | Vacuolar protein sorting 4a (yeast)            | 1.64 | 0.03 |
| Clqbp       | Complement component 1, q subcomponent binding protein | 1.53 | 0.10 |
| Exosc2_predicted | Exosome component 2 (predicted) | 1.52 | 0.10 |
| Map3k6_predicted | Mitogen-activated protein kinase kinase kinase 6 (predicted) | 1.51 | 0.09 |
| Retna       | Resistin like alphah                          | 0.05 | 0.03 |
| Crsp2       | Cysteine and glycine-rich protein 2            | 0.10 | 0.03 |
| Dmrtal1_predicted | Doublesex and mab-3 related transcription factor like family A1 (predicted) | 0.11 | 0.00 |
| Rax         | Retina and anterior neural fold homeobox       | 0.13 | 0.04 |
| Ide         | Insulin degrading enzyme                       | 0.14 | 0.02 |
| Opcml       | Opioid-binding protein/cell adhesion molecule-like | 0.17 | 0.01 |
| Wdr22_predicted | WD repeat domain 22 (predicted) | 0.18 | 0.05 |
| Novo1       | Neuro-ontological ventral antigen 1            | 0.19 | 0.02 |
| Fg220       | Fibroblast growth factor 20                   | 0.21 | 0.01 |
| Adh6        | Alcohol dehydrogenase 6 (class V)             | 0.22 | 0.02 |
| Cpg1        | Candidate plasticity gene 1                   | 0.22 | 0.04 |
| Pfkb2       | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 | 0.27 | 0.10 |
| Gph2        | Glycoprotein hormone alpha 2                  | 0.31 | 0.01 |
| Mtc21       | Myelin transcription factor 1-like             | 0.31 | 0.06 |
| Npfr2       | Neuropeptide FF receptor 2                    | 0.33 | 0.07 |
| Csn2        | Casein beta                                   | 0.34 | 0.06 |
| Syb1        | Synaptobrevin-like 1                          | 0.34 | 0.04 |
| Efcbp2      | Neuronal calcium binding 2                    | 0.40 | 0.06 |
| Cbr3_predicted | Carbonyl reductase 3 (predicted) | 0.41 | 0.03 |
| Alpi        | Alkaline phosphatase 1, intestinal, defined by SSR | 0.41 | 0.04 |
| Nrnx1       | Neurexin 1                                    | 0.43 | 0.06 |
| Gp2         | Glycoprotein 2 (zymogen granule membrane)     | 0.46 | 0.03 |
| Cd248_predicted | CD248 antigen, endosialin (predicted)   | 0.46 | 0.05 |
| Ppya3       | Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 3 | 0.59 | 0.02 |
| Zif65b0n_predicted | Zinc finger protein 580 (predicted)   | 0.62 | 0.05 |
| Ptg1lip     | Pituitary tumour-transforming 1 interacting protein | 0.65 | 0.05 |

Only annotated genes with a 50% or higher fold change are included. In all cases the FC at days 5–14 was not significantly different from the control (significance at P > 0.10 to exclude transcripts not specifically upregulated or downregulated at only day 2).
### Table 3: Genes modulated specifically at day 14

| Gene symbol | Gene name                                               | FC  | SEM  |
|-------------|---------------------------------------------------------|-----|------|
| Tbx15_predicted | T-box 15 (predicted)                                    | 8.00| 1.74 |
| Trhr          | Thyrotropin releasing hormone receptor                   | 5.67| 1.26 |
| Ppp3cc        | Protein phosphatase 3 (formerly 2B); catalytic subunit, gamma isofrom (calcineurin A gamma) | 5.07| 3.34 |
| Eif2ak3       | Eukaryotic translation initiation factor 2 alpha kinase 3 | 4.92| 2.25 |
| Hrh3          | Histamine receptor H3                                    | 4.35| 1.34 |
| Krfl5         | Kruppel-like factor 15                                   | 3.58| 0.39 |
| Gldc_predicted| Glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P) (predicted) | 3.40| 1.49 |
| Trdn          | Triadin                                                 | 3.18| 0.53 |
| Galr1         | Galanin receptor 1                                       | 3.15| 0.04 |
| Mlana_predicted| Melan-A (predicted)                                     | 2.30| 0.47 |
| Cma1          | Chymase 1, mast cell                                     | 2.15| 0.30 |
| Trerf1_predicted| Transcriptional regulating factor 1 (predicted)          | 1.91| 0.10 |
| Serbp1        | Serpine 1 mRNA binding protein 1                         | 1.85| 0.22 |
| Ltb4dh        | Leukotriene B4 12-hydroxydehydrogenase                   | 1.78| 0.24 |
| Fgf1          | Fibroblast growth factor                                 | 1.75| 0.28 |
| Ace           | Angiotensin 1 converting enzyme                           | 1.72| 0.33 |
| Eif4a1        | Eukaryotic translation initiation factor 4A1             | 1.68| 0.38 |
| Adar          | Adenosine deaminase, RNA-specific                        | 1.59| 0.12 |
| Dsb1          | Damage-specific DNA binding protein 1                     | 1.57| 0.05 |
| Mbn1          | Muscleblind-like 1 (Drosophila)                          | 1.52| 0.10 |
| Lrtrs1        | Leucine zipper, putative tumour suppressor                | 1.52| 0.16 |
| Hmga1         | High mobility group AT-hook 1                            | 1.51| 0.13 |
| Apoa5         | Apolipoprotein A-V                                      | 0.08| 0.01 |
| Olfm3         | Olfactomedin 3                                           | 0.09| 0.05 |
| Cdc215        | Cell division cycle 2-like 5 (cholinesterase-related cell division controller) | 0.11| 0.03 |
| Prom2         | Prominin 2                                               | 0.11| 0.02 |
| Snag1_predicted| Sorting nexin associated golgi protein 1 (predicted)     | 0.11| 0.03 |
| Serpina3m     | Serine (or cysteine) proteinase inhibitor, clade A, member 3M | 0.12| 0.02 |
| Ank1_predicted| Ankyrin 1, erythroid (predicted)                         | 0.13| 0.00 |
| Histh1t       | Histone 1, h1t                                           | 0.15| 0.02 |
| Imp1          | Insulin-like growth factor 2, binding protein 1          | 0.15| 0.03 |
| Cacng7        | Calcium channel, voltage-dependent, gamma subunit 7     | 0.16| 0.05 |
| Drpr2         | Dystrophin-related protein 2 A-form splice variant       | 0.20| 0.03 |
| Eif4g1        | Eukaryotic translation initiation factor 4 gamma, 1      | 0.20| 0.01 |
| Apob          | Apolipoprotein B                                         | 0.21| 0.07 |
| Wt1           | Wilms tumor 1                                            | 0.23| 0.02 |
| Pql2_predicted| PQ loop repeat containing 2 (predicted)                  | 0.25| 0.07 |
| Cnr1          | Cannabinoid receptor 1 (brain)                           | 0.25| 0.02 |
| Lmo3          | LIM domain only 3                                         | 0.26| 0.03 |
| Bai3_predicted| Brain-specific angiogenesis inhibitor 3 (predicted)       | 0.28| 0.04 |
| Sp3           | Sp3 transcription factor                                 | 0.31| 0.02 |
| Apba1         | Amyloid beta (A4) precursor protein-binding, family A, member 1 | 0.32| 0.03 |
| Kcnc3         | Potassium voltage gated channel, Shaw-related subfamily, member 3 | 0.44| 0.06 |
| Actc1         | Actin alpha cardiac 1                                    | 0.45| 0.06 |
| Wnt11         | Wingless-type MMTV integration site family, member 11    | 0.47| 0.09 |
| Iil2          | Interleukin 2                                            | 0.50| 0.08 |
| Galnt2_predicted| UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2 (predicted) | 0.57| 0.02 |
| Nrg2          | Neuregulin 2                                             | 0.60| 0.04 |
| Cspg4         | Chondroitin sulphate proteoglycan 4                      | 0.60| 0.02 |
| Enth           | Enthoprotein                                             | 0.61| 0.03 |
| Zfp503_predicted| Zinc finger protein 503 (predicted)                      | 0.66| 0.02 |
| Rbm3          | RNA binding motif (RNP1, RRM) protein 3                   | 0.66| 0.02 |
| Mps5_predicted| Membrane protein, palmitoylated 5 (MAGUK p55 subfamily member 5) (predicted) | 0.66| 0.01 |
| Prgl          | Plasticity related gene                                  | 0.67| 0.02 |
| Csnkld        | Casein kinase 1, delta                                   | 0.67| 0.06 |

Only annotated genes with a 50% or higher fold change are included. In all cases the FC at days 2 – 7 was not significantly different from the control (significance at P > 0.10 to exclude transcripts that were not specifically upregulated or downregulated at only day 14).
**Figure 4**

**Behaviour over time of genes involved in inflammation and immune response.** Upregulated genes are shown in red and downregulated genes in blue. Gene expression was considered significantly changed by inflammation at p < 0.05 after analysis of variance followed by Tukey post-hoc tests and Benjamini & Hochberg false discovery rate correction.

| Gene Symbol | Gene Name                                      |
|-------------|-----------------------------------------------|
| A2m         | alpha-2-macroglubulin                          |
| Alx15       | arachidonate 12-lipoxygenase                   |
| Alx5        | arachidonate 5-lipoxygenase                    |
| C3          | complement component 3                        |
| Ccl2        | MCP-1                                          |
| Ccl3        | MIP-1a                                         |
| Ccl4        | Mip-1b                                         |
| Ccr1        | Mip-1x receptor                                |
| Ccr2        | chemokine (C-C motif) receptor 2              |
| Ccr5        | chemokine (C-C) receptor 5                    |
| Chit31      | chitinase 3-like 1                             |
| Csf3        | colony stimulating factor 3 (granulocyte)     |
| Csf3r       | colony stimulating factor 3 receptor (granulocyte) |
| Cxcl1       | Gro-α                                          |
| Cxcl12      |stromal cell-derived factor 1                  |
| Cxcl14      | Chemokine (C-X-C motif) ligand 14              |
| Cxcl2       | Gro-β/Cxcl-2/Mip-2                            |
| Cxcl5       | CXC chemokine LIX                              |
| Cxcr4       | chemokine (C-X-C motif) receptor 4            |
| Cytb        | cytochrome b-245, beta polypeptide (Gpi91-phox) |
| Gmt1980     | gene model 1980, (NCBI)                        |
| Gpr109a     | G protein-coupled receptor 109A                |
| Icam1       | intercellular adhesion molecule 1             |
| Il10        | interleukin 10                                 |
| Il1a        | interleukin 1 alpha                            |
| Il1b        | interleukin 1 beta                             |
| Il1r2       | interleukin 1 receptor, type II               |
| Il1r1p      | interleukin 1 receptor accessory protein       |
| Il1m        | interleukin 1 receptor antagonist              |
| Il2         | interleukin 2                                  |
| Il2ra       | interleukin 2 receptor, alpha chain           |
| Il2tg       | interleukin 2 receptor, gamma (severe combined immunodeficiency) |
| Il6         | interleukin 6                                  |
| Il7         | interleukin 7                                  |
| Il8b        | Cxcr2                                          |
| Lbp         | lipopolysaccharide binding protein             |
| Lyz         | Lysozyme                                       |
| Nfkb1       | nuclear factor of kappa light chain gene enhancer in B-cells, p105 |
| Nfkb2       | nuclear factor of kappa light polypeptide gene enhancer in B-cells, p489p100 |
| Nfkbia      | nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha |
| Nos1        | nitric oxide synthase 1, neuronal             |
| Nos2        | nitric oxide synthase 2, inducible            |
| Pias2g2a    | phospholipase A2, group IA (platelets, synovial fluid) |
| Pges         | prostaglandin E synthase                     |
| Phtgs2      | prostaglandin-endoperoxide synthase 2         |
| S100a8      | calgranulin A                                 |
| S100a9      | calgranulin B                                 |
| Selp        | selectin, platelet                            |
| Sod2        | superoxide dismutase 2, mitochondrial         |
| Tgfβ1       | transforming growth factor, beta 1            |
| Trc2        | toll-like receptor 2                          |
| Trc7        | toll-like receptor 7 (predicted)              |
| Tnf         | tumor necrosis factor                         |
| Xdh         | xanthine dehydrogenase                        |
Il23a, Il6 and Tgb1 are indicative of Th17 induction [26]. In fact, although Il17a was not represented in the microarray, qRT-PCR findings showed an increase in the mRNA levels (data not shown), suggesting the involvement of Th17 cells in rat TNBS colitis. A contribution of Th1 cells is also likely in view of the Ifng upregulation and lack of Il4 changes, although Il12a and Il12b were not augmented. Our group [27] and other authors [28,29] previously reported an increase in the IFN-γ or IFN-γ/IL-4 protein ratio in this model. A staggering increase was observed in some of the genes, e.g. S100a9/S100a8, suggesting that they may be highly sensitive markers to follow intestinal inflammation, as previously observed in humans [30,31]. These genes encode proteins expressed by macrophages and neutrophils and are involved in bacterial defence, chemotaxis and signalling [32,33].

Analysis of the microarray data offered insights into the nature of the inflammatory infiltrate. TNBS colitis was previously characterized at this level [25]. In brief, macrophages and neutrophils are initially recruited to the colonic mucosa and submucosa, followed by a more predominant role of lymphocytes in later stages of colitis, which are characterized by progressive healing, reepithelialization, crypt enlargement and prominent fibrosis [25]. The predominance of neutrophils/macrophages in the inflammatory response was confirmed in our study by the global increase in gene markers of these cell types and the absence of effects on B, T and NK cells (at significance level of p < 0.05). It should be noted that the sample used for genomic analysis did not include lymphoid follicles, in which lymphocytes accumulate in this model [25], which explains the lack of a significant increase. However, gene ontology analysis indicated that lymphocyte differentiation was already prominent at day 5.

Our data also revealed important changes that were not directly linked to inflammation/immunity. Thus, marked alterations were found in metabolism-related genes, indicating a reduced functionality of numerous biochemical pathways, including glycolysis, purine biosynthesis, Krebs cycle, cholesterol biosynthesis and transport, fatty acid biosynthesis and respiratory chain. Taken together, these data demonstrate a decrease in biosynthesis of macromolecules, an increase in catabolism, and a decrease in aerobic and anaerobic respiration. Therefore, mucosal cells may be have inadequate energy resources during the inflammatory response. Similar changes have been reported in IBD patients [34] and in experimental colitis [35].

A number of genes encoding ion transporters were affected by TNBS colitis, including: Atp1a1, encoding the catalytic subunit of the Na+/K+ pump; Scnn1a, encoding the alpha polypeptide of the epithelial sodium channel; Nhe1, encoding the housekeeping Na+/H+ exchanger; and Slc12a2, encoding Nkcc2, the Na+/K+/Cl- cotransporter. These were generally downregulated, as were the transporters involved in NaCl absorption, e.g., Nhe2, Nhe3, and Slc26a3. However, Cftr was unchanged. These modifications are consistent with severe alterations of ionic transport, as demonstrated in IBD and animal models [17,36,37].

A striking finding of our analysis was the vast number of upregulated genes involved in tissue remodelling in TNBS colitis, generally during the chronic phase, as indicated by the gene ontology analysis. The chronic phase is characterized by mucosal wound healing and submucosal fibrosis and by the scarring and deposition of excess muscular tissue, extending through day 14 and eventually leaving sequelae [5]. These features are often detectable by the naked eye as colonic shortening, deformation and rigidity. Two features are related to the intestinal fibrosis suffered by IBD patients: an increase in collagen synthesis by smooth muscle cells, fibroblasts and myofibroblasts, and an increase in muscle layer thickness. IGFBP-5 expression is known to increase in ulcerative colitis, while IGF-1 and TGF-β1 expression is known to increase in both ulcerative colitis and Crohn’s disease [38,39]. These molecules have been related to extracellular matrix remodelling and may therefore be relevant to the fibrosis observed in IBD. Our results are in agreement with these IBD findings, showing an increase in Igf1, Igfbp5 and Tgb1 expression in the inflamed colon. Hence, the TNBS model may be appropriate for the study of molecular mechanisms implicated in the development of fibrosis in intestinal inflammation. In addition, expressions of procollagen/collagen genes, most

Figure 5
Postgenomic validation of selected inflammation genes by qRT-PCR. *p < 0.05 vs. control.
### Figure 6

**Behaviour over time of genes involved in metabolism.** Upregulated genes are shown in red and downregulated genes in blue. Gene expression was considered significantly changed by inflammation at $p < 0.05$ after analysis of variance followed by Tukey post-hoc tests and Benjamini & Hochberg false discovery rate correction.
notably Tgm1, and of several enzymes related to collagen processing were increased in the TNBS colitic animals.

Our results include some intriguing findings, including: the severe repression of nuclear receptors Nr1d1 and Nr1d2, involved in circadian expression patterns and recently shown to be regulated by heme [40]; the synthesis and marked upregulation of Tg in the inflamed colon; and the downregulation of the thyroid receptor. Further experiments are warranted to clarify the role of these changes in colonic inflammation.

We were especially interested in establishing a correlation between the known characteristics of the model and the time course of gene expression. Because the time points selected cover all stages of the TNBS-induced inflammatory response, from acute (2 d) to chronic (5–7 d) and healing/recovery (14 d) phases, we expected to find substantial differences in the pattern of expression. For instance, genes involved in inflammation/immunity and tissue regeneration were expected to predominate in the early and late stages, respectively. However, the vast majority of transcripts followed a common trend, namely a change of expression that was maximal at days 5 and 7, when colitis is most prominent, and was normal (or almost normal) at day 14. Hence, there is a close correlation between the pathological features of TNBS colitis and the changes observed in the transcriptome. The genes that were up- or downregulated only at days 2 or 14 did not conform to any specific category. Some of the transcripts involved are of interest. Thus, Retnla, which encodes resistin-like alpha, which is dramatically repressed soon after colitis induction, may be involved in monocyte activation, as is the beta isoform [41]. Both Ace and Cma1, which encode enzymes with angiotensin I cleaving capacity, are induced specifically at day 14. Some specific receptors involved in cellular signalling are differentially regulated, such as Galr1, Hrh3, Npffr2 and Cn1r1. Further analysis is warranted to explore the implications of these findings.

Despite using a technical approach (triplicate samples per time point) that meets or surpasses common standards in genomic studies, we carried out more than 1100 qRT-PCR determinations in 15 additional samples for a posteriori data validation. As expected, the overall correlation was excellent. In some cases, microarray analysis appeared to be less prone to pick up statistically significant variations, i.e., it was less sensitive than qRT-PCR. The fact that we examined four different time points adds to the complexity of the analysis, since a marked change at one time point may not be enough in many cases to reach significance in the ANOVA. Further validation is provided by the fact that the changes (or lack thereof) observed in many genes, including Il1b, Il1rn, Cfr, Tnf, Alpl, Alpi, Ifng, Il4, Il6, Pgs2, Nos2 and Ccl2, among many others, are in line with previous observations from our own group, either at the RNA or protein level [12,18,27].

Previous studies have examined changes in the transcriptome in intestinal inflammation, especially in mouse colitis elicited by TNBS and other manoeuvres [6-10]. These studies are somewhat limited because they either use small microarrays, examine animals shortly after colitis induction (consistent with acute but not chronic colitis), offer limited or no postgenomic validation or use longitudinal tissue samples. One of these studies addressed the time course of gene expression, but it studied recovery from repeated TNBS challenges [9]. In general, the changes in gene expression documented in the present study are much stronger and wider than those found in previous reports. For example, 175 genes were differentially expressed in the above study in compared to the thousands of genes in our investigation. On the other hand, there have been several human IBD microarray studies [30,31,42-47], which have detected some key gene expression changes associated with human intestinal inflammation, including some specifically linked to either ulcerative colitis or Crohn’s disease [47]. However, it is poorly understood how genomic data are related to IBD pathology and therapy, partly because of the variability inherent to human studies and partly because of methodological differences [48]. For instance, the most important source of variation in gene expression measurement (54%) is the microarray platform itself [49], and all of the above studies used different arrays. There are also differences in design and especially in sample selection, i.e., individual vs. pooled or mucosal vs. full thickness. Nevertheless, there are some similarities with the rat TNBS model, including increases in Chi3l1, Mmp3, 10 and 12,
Figure 8
Behaviour over time of genes involved in cell signalling. Upregulated genes are shown in red and downregulated genes in blue. Gene expression was considered significantly changed by inflammation at \( p < 0.05 \) after analysis of variance followed by Tukey post-hoc tests and Benjamini & Hochberg false discovery rate correction.

| Gene Symbol | Gene Name |
|-------------|-----------|
| Ace         | angiotensin 1 converting enzyme |
| Adcy4       | adenylate cyclase 4 |
| Adcy5       | adenylate cyclase 5 |
| Adcy7       | adenylate cyclase 7 |
| Bcl2a1      | B-cell leukemia/lymphoma 2 related protein A1 |
| Camk2d      | calcium/calmodulin-dependent protein kinase II, delta |
| Cnr1        | cannabinoid receptor 1 (brain) |
| Dpde1       | phosphodiesterase 4C, cAMP-specific |
| Edn1        | endothelin 1 |
| Edn2        | endothelin 2 |
| Gp49b       | glycoprotein 49b |
| Htr2b       | 5-hydroxytryptamine (serotonin) receptor 2B |
| Inhbb       | Inhibin beta-B |
| Itpr1       | inositol 1,4,5-triphosphate receptor 1 |
| Junb        | Jun-B oncogene |
| Map3k8      | mitogen-activated protein kinase kinase kinase 8 (Tpl-2) |
| Nox4        | NADPH oxidase 4 |
| Nr1d1       | nuclear receptor subfamily 1, group D, member 1 |
| Nr1d2       | nuclear receptor subfamily 1, group D, member 2 |
| P2ry2       | purinergic receptor P2Y, G-protein coupled 2 |
| P2ry6       | pyrimidinergic receptor P2Y, G-protein coupled, 6 |
| Pde1c       | phosphodiesterase 1C |
| Pde4b       | phosphodiesterase 4B |
| Plek        | pleckstrin |
| Ppp1cb      | protein phosphatase 1, catalytic subunit, beta isoform |
| Pppr1a      | protein phosphatase 1, regulatory (inhibitor) subunit 1A |
| Pppr1b      | protein phosphatase 1, regulatory subunit 9B |
| Prkaca      | protein kinase, cAMP-dependent, catalytic, alpha |
| Prkar2a      | protein kinase, cAMP-dependent, regulatory, type 2, alpha |
| Prkar2b      | protein kinase, cAMP-dependent regulatory, type II beta |
| Prkc         | protein kinase C, alpha |
| Prkch        | protein kinase C, eta |
| Prkcz        | protein kinase C, zeta |
| Ptger2      | prostaglandin E receptor 2, subtype EP2 |
| Ptger4      | prostaglandin E receptor 4, subtype EP4 |
| Sstr1       | somatostatin receptor 1 |
| Tacr2       | tachykinin receptor 2 |
| Tg           | thyroglobulin |
| Thra         | thyroid hormone receptor alpha |
| Vip          | vasoactive intestinal polypeptide |
Apoe, S100a8, Ltb, Sod2, Cxcl1, Cxcl2, Il6 and many other genes.

**Conclusion**

We have characterized the rat TNBS model of IBD at the genomic level, obtaining novel data on individual genes, metabolic pathways and biological functions that are altered during colitis. These findings establish a basis for further mechanistic studies on drug action and research into the pathophysiology of intestinal inflammation. The full genomic database will serve as a reference standard for all future investigations using this model and for comparisons with other animal models of colitis, an approach that is currently being applied in our laboratory.

**Abbreviations**

IBD: inflammatory bowel disease; IL: interleukin; qRT-PCR: quantitative real time PCR; TNBS: trinitrobenzenesulphonic acid.
Figure 11
**Behaviour over time of genes involved in tissue remodelling.** Upregulated genes are shown in red and downregulated genes in blue. Gene expression was considered significantly changed by inflammation at $p < 0.05$ after analysis of variance followed by Tukey post-hoc tests and Benjamini & Hochberg false discovery rate correction.

| Gene Symbol | Gene Name                                      |
|-------------|------------------------------------------------|
| Cav         | caveolin                                       |
| Cav2        | caveolin 2                                     |
| Cdh13       | cadherin 13                                    |
| Col11a1     | procollagen, type XI, alpha 1                  |
| Col12a1     | procollagen, type XII, alpha 1                 |
| Col15a1     | procollagen, type XV (predicted)               |
| Col18a1     | collagen, type XVIII, alpha 1                  |
| Col1a1      | collagen, type 1, alpha 1                      |
| Col1a2      | procollagen, type I, alpha 2                   |
| Col4a1      | procollagen, type IV, alpha 1 (predicted)      |
| Col5a3      | collagen, type V, alpha 3                      |
| Col6a3      | procollagen, type VI, alpha 3 (predicted)      |
| Col8a1      | procollagen, type VIII, alpha 1 (predicted)    |
| Cthrc1      | collagen triple helix repeat containing 1      |
| Emilin1     | elastin microfibril interfacser 1 (predicted)  |
| Emilin2     | elastin microfibril interfacser 2              |
| Fbn2        | fibrillin 2                                     |
| Fn1         | fibronectin 1                                  |
| Gja4        | gap junction membrane channel protein alpha 4  |
| Gja5        | gap junction membrane channel protein alpha 5  |
| Igf1        | insulin-like growth factor 1                   |
| Igfbp5      | insulin-like growth factor binding protein 5    |
| Lox         | lysyl oxidase                                   |
| Mmp12       | matrix metallopeptidase 12                     |
| Mmp14       | matrix metalloproteinase 14 (membrane-inserted)|
| Mmp2        | matrix metallopeptidase 2                      |
| Mmp7        | matrix metalloproteinase 7                     |
| Mmp8        | matrix metallopeptidase 8                      |
| Mmp9        | matrix metallopeptidase 9                      |
| Msn         | moesin                                         |
| Muc3        | mucin 3                                        |
| Myh10       | myosin heavy chain 10, non-muscle              |
| Mylk        | myosin, light polypeptide kinase (predicted)   |
| Myo1f       | myosin IF (predicted)                          |
| Myo5a       | myosin Va                                      |
| Myo5c       | myosin VC (predicted)                          |
| P4ha1       | procollagen-proline, 2-oxoglutarate 4-dioxygenase, alpha 1 polypeptide |
| Pcolce      | procollagen C-proteinase enhancer protein      |
| Pln         | phospholamban                                 |
| Smtn        | smoothelin (predicted)                         |
| Tfh1        | trefoil factor 1                               |
| Tfh2        | trefoil factor 2 (spasmolytic protein 1)       |
| Tfh3        | trefoil factor 3                               |
| Tgm1        | transglutaminase 1                             |
| Tgm2        | transglutaminase 2, C polypeptide              |
| Timp1       | tissue inhibitor of metalloproteinase 1        |
| Tpm1        | tropomyosin 1, alpha                           |
| Vill        | villin (predicted)                            |
| Vill2       | villin 2                                       |

-7.18 - 0 +7.18
Figure 12
Postgenomic validation of selected tissue remodeling genes by qRT-PCR. *p < 0.05 vs. control.

Authors' contributions
FSMLH and OMA conducted the animal experiments, coordinated the bioinformatic analysis of the microarray and qRT-PCR data and drafted the manuscript. FSMLH, OMA, MDS and AZ conceived the study. All authors contributed to the interpretation of the data and have read and approved the final manuscript.

Acknowledgements
The authors acknowledge the technical help of Dietmar Fernández and David Arctica from Progenika Biopharma and the assistance of the European and approved the final manuscript.

References
1. Sands BE: Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007, 42:16-25.
2. Jurjus AR, Khoury NN, Reinmund JM: Animal models of inflammatory bowel disease. J Pharmacol Toxic Methods 2004, 50:81-92.
3. Neurath M, Fuss I, Strober W: TNBS-colitis. Int Rev Immunol 2000, 19:51-62.
4. Sanchez de Medina F, Galvez J, Romero JA, Zarzuelo A: Effect of quercetin on acute and chronic experimental colitis in the rat. J Pharmacol Exp Ther 1996, 278:771-779.
5. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989, 96:795-803.
6. Yamamoto S, Isuzu K, Takahashi Y, Murase Y, Iwai M, Arisawa T, Nakano H, Nishimura K, Yamao S, Hata M, Isaiwai M, Oda Y, Takei M, Otsuka Y, Ikawa K, Nakata M, Hori T, Ozaki H, Imakawa K: Intestinal gene expression in TNBS-treated mice using genechip and subtractive cDNA analysis: implications for Crohn’s disease. Biol Pharm Bull 2005, 28:2046-2053.
7. Abad C, Juarranz Y, Martinez C, Arranz A, Rosignoli F, Garcia-Gomez M, Leceta J, Gomariz RP: cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm Bowel Dis 2005, 11:674-684.
8. te Velde AA, de Kort F, Sterrenburg E, Pronk I, ten Kate FJ, Hommes DW, van Deventer SJ: Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:325-330.
9. Wu F, Chakravarti S: Differential expression of inflammatory and fibrogenic genes and their regulation by NF-kappaB inhibition in a mouse model of chronic colitis. J Immunol 2001, 179:6988-7000.
10. Rivera E, Flores I, Rivera E, Appleyard CB: Molecular profiling of a rat model of colitis: validation of known inflammatory genes and identification of novel disease-associated targets. Inflamm Bowel Dis 2006, 12:950-966.
11. Gonzalez R, Sanchez de Medina F, Martinez-Augustin O, Nieto A, Galvez J, Rico S, Zarzuelo A: Anti-inflammatory effect of dexametin in hapten-induced colitis in the rat. Br J Pharmacol 2004, 141:951-960.
12. Daddaoua A, PUerta V, Zarzuelo A, Suarez MD, Sanchez de Medina F, Martinez-Augustin O: Bovine glycomacropeptid is anti-inflammatory in rats with hapten-induced colitis. J Nutr 2005, 135:1164-1170.
13. Krawisz E, Sharon P, Stenson WF: Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gas troenterology 1984, 87:1344-1350.
14. Salomonis N, Hanspers K, Zhang AC, Vranizan K, Lawlor SC, Dahlquist KD, Doniger SW, Stuart J, Conklin BR, Pico AR. GenMAPP 2: new features and resources for pathway analysis. BMC Bioinformatics 2007, 8:217.
15. Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR. MAPPfinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol 2003, 4:R7.
16. Braweza A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoekert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glissoni P, Holstege FC, Kim IF, Markowitz V, Mattse JJ, Parkinson H, Robinson A, Sarkans U, Schreiner K, Stewart J, Taylor R, Vilo J, Vingron M. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001, 29:365-371.
17. Sanchez de Medina F, Perez R, Martinez-Augustin O, Gonzalez R, Lorente MD, Galvez J, Zarzuelo A: Disturbances of colonic ion secretion in inflammation: role of the enteric nervous system and cAMP. Pflugers Arch 2002, 444:378-388.
18. Sanchez de Medina F, Martinez-Augustin O, Gonzalez R, Ballesta I, Nieto A, Galvez J, Zarzuelo A: Induction of alkaline phosphatase in the inflamed intestine: a novel pharmacological target for inflammatory bowel disease. Biochem Pharmacol 2004, 68:2317-2326.
27. Pérez-Navarro R, Ballester I, Zarzuelo A, Sánchez de Medina F. Dis- 
turbances in epithelial ionic secretion in different experi- 
mental models of colitis. Life Sci 2005, 76:1489-1501.
28. Stasi MA, Ruggiero V, Ursillo A, Taurelli R, Agliano M, Weber E, 
Lorenzoni P, Sorrentino V, Pacifici L, Carminati P. Ameliorating 
effects of the immunomodulator 3-(2-ethylphenyl)-5-(3- 
 methoxypyphenyl)-1H-1,2,4-triazole in an experimental model 
of colitis in the rat. Eur J Pharmacol 2004, 494:263-272.
29. Sun FF, Lai PS, Yue G, Yin K, Nagale RG, Tong DM, Krz esicki RF, Chin 
JE, Wong PY. Pattern of cytokine and adhesion molecule 
mRNA in hapten-induced relapsing colon inflammation in 
the rat. Inflammation 2001, 25:33-43.
30. Lawrance IC, Fiocchi C, Chakravarti S: Ulcerative colitis and 
Crohn's disease: distinctive gene expression profiles and 
novel susceptibility candidate genes. Hum Mol Genet 2001, 
10:445-456.
31. Dieckgraefe BK, Stenson WF, Korzenik JR, Swanson PE, Harrington 
CA: Analysis of mucosal gene expression in inflammatory 
bowel disease by parallel oligonucleotide arrays. 
RNA Genomics 2000, 4:1-11.
32. Raquili MA, Anceriz N, Rouleau P, Tessier PA: Blockade of Anti-
microbial Proteins S100A8 and S100A9 Inhibits Phagocyte 
Migration to the Alveoli in Streptococcal Pneumonia. J Immu- 
noL 2008, 180:3366-3374.
33. Gebhardt C, Riehl A, Durdeviqi M, Nemeth J, Furstenberger G, 
Muller-Decker K, Eink A, Arnold B, Bierhaus A, Nawroth PP, Hess J, 
Angel P: RAGE signaling sustains inflammation and promotes 
tumor development. J Exp Med 2008, 205:275-285.
34. Heimler S, Moehle C, Zahn A, Boettcher A, Stremmel W, Langmann 
T, Schmitz G. Alterations in intestinal fatty acid metabolism in 
inflammatory bowel disease. Biochim Biophys Acta 2006, 
1762:341-350.
35. Megar J, Bursell M, Gerdin AK, Svensson L, Michaelsson E. Bohloolly- 
Y M: Mice with experimental colitis show an altered metabo-
lism with decreased metabolic rate. Am J Physiol Gastrointest Liver 
Physiol 2007, 292:G165-G172.
36. Supi K, Musch MW, Field M, Chang EB: Inhibition of Na+,K- 
ATPase by interferon gamma down-regulates intestinal epi-
thelial transport and barrier function. Gastroenterology 2001, 
120:1393-1403.
37. Martinez-Augustin O, Romero-Calvo I, Suarez MD, Zarzuelo A, 
Sanchez de Medina F. Molecules of impaired water and ion 
movements in inflammatory bowel diseases. Inflammatory 
Bowel Diseases 2008. DOI 10.1002/ibd.20579
38. Zimmermann EM, Li L, Hou YT, Mohapatra NK, Pociulowska JB: Insu-
lin-like growth factor I and insulin-like growth factor binding 
protein 5 in Crohn's disease. Am J Physiol Gastrointest Liver 
Physiol 2001, 280:G1022-G1029.
39. Lawrance IC, Maxwell L, Doe W: Inflammation location, but not 
type, determines the increase in TGF-beta1 and IGF-1 
protein 5 in Crohn's disease. Inflamm Bowel Dis 2004, 
10:207-213.
40. Dooley TP, Curro EV, Reddy SP, Davis RL, Lambert GW, Wilborn 
TW, Elton CO: Regulation of gene expression in inflammatory 
bowel disease and correlation with IBD drugs: screening by 
DNA microarrays. Inflamm Bowel Dis 2004, 10:1-14.
41. Langmann T, Moehle C, Mau erer R, Scharl M, Liebisch G, Zahn A, 
Stremmel W, Schmitz G. Loss of detoxification in inflammatory 
bowel disease: dysregulation of pregnant X receptor target 
genes. Gastroenterology 2004, 127:26-40.
42. Costello CM, Mah N, Hasler R, Rosenstiel P, Waezig GH, Hahn A, 
Lu T, Gurbux Y, Nikolaus S, Albrecht M, Hampe J, Lucas R, Kloppe1 
G, Eichhoff H, Lehrhach L, Heng lauer D, Schreiber S. Dissection of 
the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med 2005, 2:e199.
43. Wu F, Dissopoulos T, Cope L, Maitra A, Brant SR, Harris ML, Bayless 
TM, Parmigiani G, Chakravarti S: Genome-wide gene expression 
differences in Crohn's disease and ulcerative colitis from 
endoscopic pinch biopsies: insights into distinctive pathogen-
ism. Inflamm Bowel Dis 2007, 13:807-821.
44. Collag C, Nielsen O, Borup R, Nielsen FC. Microarrays and 
Crohn's disease: collecting reliable information. Scand J Gas-
troenterol 2005, 40:369-377.
45. Bammiller T, Beyer RP, Bhattacharya S, Boorman GA, Boyles A, Brad-
ford BU, Bungnarre R, Bushel PR, Chaturvedi K, Choi D, Cunning-
ham ML, Deng S, Dressman KH, Fannin RD, Farin FM, Freedman JH, Hry 
RC, Harper A, Humble MC, Hurbans P, Kavanagh TJ, Kaufman WK, 
Kerr KF, Jing L, Lapidus JA, Lasarev MR, Li J, Li J, Lobenhofer 
EK, Lu X, Malek RL, Milton S, Nagalla SR, O'malley JP, Palmer VS, Pat-
tee P, Paulus RS, Perou CM, Phillips K, Qin LX, Qu Y, Quigley SD, 
Roddman M, Rusyn I, Samson LD, Schwarz DA, Shi Y, Shin JI, Sieber 
SO, Sifter S, Speer MC, Spencer PS, Sproles DI, Swenberg JA, Suk WA, 
Sullivan RC, Tian R, Tennant RW, Todd SA, Tucker CJ, Van Houten 
B, Weis BK, Xuan S, Zarbl H: Standardizing global gene expres-
sion analysis between laboratories and across platforms. Not 
Methods 2005, 2:351-356.